Shuang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuang Liu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Yang Zhou
School of Health Sciences, Purdue University, IN 47907, USA
11 shared publicationsShundong Ji
School of Health Sciences, Purdue University, IN, 47907, USA
9 shared publications- Wei Fang
Department of Nuclear Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 shared publications Yumin Zheng
Department of Nuclear Medicine, China-Japan Friendship Hospital, Beijing, 100037, China
6 shared publicationsMin Liu
School of Health Sciences, Purdue University , 550 Stadium Mall Drive, West Lafayette, Indiana 47907, United States
5 shared publicationsYong Yang
International Medicine Center, International Medicine Division, Beijing Friendship Hospital, Capital Medical University, Beijing, China; Department of Nuclear Medicine, Fuwai Hospital, the National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications
Latest Publications
- 16 March 2020
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 28 (6) , 2687-2696
99mTc-3SPboroxime: A neutral 99mTc(III) radiotracer with high heart uptake and long myocardial retention
- 16 March 2020
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 28 (6) , 2687-2696
99mTc-3SPboroxime: A neutral 99mTc(III) radiotracer with high heart uptake and long myocardial retention
- 1 June 2019
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 148, 168-177
68Ga-labeled dimeric and trimeric cyclic RGD peptides as potential PET radiotracers for imaging gliomas
- 1 June 2019
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 148, 168-177
68Ga-labeled dimeric and trimeric cyclic RGD peptides as potential PET radiotracers for imaging gliomas
- 27 December 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (1) , 319-328
Sulfonyl-Containing Boronate Caps for Optimization of Biological Properties of 99mTc(III) Radiotracers [99mTcCl(CDO)(CDOH)2B-R] (CDOH2 = Cyclohexanedione Dioxime)
In this study, different boronate caps were used to optimize biodistribution properties of radiotracers [99mTcCl(CDO)(CDOH)2B-R] (1: R = 3S; 2: R = 3SP; 3: R = 3MS; 4: R = 3DMS; 5: R = 3MSB; 6: R = 3MMS; 7: R = 3MSA; 8: R = 3DMSA; 9: R = 4S; 10: R = 4MS; and 11: R = 4MSB). Among the eleven new 99mTc radiotracers, 2 shows the most promising characteristics of an optimal heart imaging agent. Its initial heart uptake is close to that of 99mTc-Teboroxime, but its heart retention time is significantly longer. Its heart/liver, heart/lung and heart/muscle ratios are also better than those of 99mTc-Teboroxime. The SPECT image quality with 2 in SD rats is better than that with 99mTc-Teboroxime. The high initial heart uptake, long heart retention and high heart/background ratios make 2 an excellent SPECT radiotracer for MPI.
- 27 December 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (1) , 319-328
Sulfonyl-Containing Boronate Caps for Optimization of Biological Properties of 99mTc(III) Radiotracers [99mTcCl(CDO)(CDOH)2B-R] (CDOH2 = Cyclohexanedione Dioxime)
In this study, different boronate caps were used to optimize biodistribution properties of radiotracers [99mTcCl(CDO)(CDOH)2B-R] (1: R = 3S; 2: R = 3SP; 3: R = 3MS; 4: R = 3DMS; 5: R = 3MSB; 6: R = 3MMS; 7: R = 3MSA; 8: R = 3DMSA; 9: R = 4S; 10: R = 4MS; and 11: R = 4MSB). Among the eleven new 99mTc radiotracers, 2 shows the most promising characteristics of an optimal heart imaging agent. Its initial heart uptake is close to that of 99mTc-Teboroxime, but its heart retention time is significantly longer. Its heart/liver, heart/lung and heart/muscle ratios are also better than those of 99mTc-Teboroxime. The SPECT image quality with 2 in SD rats is better than that with 99mTc-Teboroxime. The high initial heart uptake, long heart retention and high heart/background ratios make 2 an excellent SPECT radiotracer for MPI.
- 30 November 2017
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 28 (12) , 2998-3006
Novel Approach for 99mTc-Labeling of Red Blood Cells: Evaluation of 99mTc-4SAboroxime as a Blood Pool Imaging Agent
Angiography with radiolabeled red blood cells (RBCs) plays an important role in diagnosis and prognosis in vascular diseases. Both in vitro and in vivo methods have been developed for 99mTc-labeling of RBCs. However, these methods are complicated and lack reproducibility. Therefore, it is highly desirable to develop an alternative method for routine 99mTc-labeling of RBCs. In this report, we present a novel approach for 99mTc-labeling of RBCs. We prepared a new 99mTc(III) radiotracer [99mTcCl(CDO)(CDOH)2B-4AS] (99mTc-4ASboroxime: 4AS-B(OH)2 = 4-aminosulfonylphenyl)boronic acid, and CDOH2 = cyclohexanedione dioxime) in >95% radiochemical purity. Imaging and biodistribution studies were performed in Sprague–Dawley (SD) rats. It was found that the blood radioactivity was ∼6.0%ID/g (∼90% injected dose for 200–225 g SD rats) for 99mTc-4ASboroxime with low uptake in the myocardium, kidneys, liver, lungs, and muscle, most likely due to lack of leakage of 99mTc-labeled RBCs from the intravascular space. The blood radioactivity was almost unchanged over the 2 h period, suggesting that the binding of 99mTc-4ASboroxime to blood components (cells, proteins, and plasma) is stable. The results from γ-counting of the isolated blood components showed that 99mTc-4ASboroxime had >95% of blood radioactivity binding to RBCs, ∼1% to albumin, and ∼3% remaining free in blood plasma, demonstrating its RBC-specificity. The results from imaging studies in SD rats indicated that 99mTc-4ASboroxime is predominantly distributed in the blood pool. Main blood vessels were well delineated in the head/neck and abdominal regions. This statement was further substantiated by the results from imaging studies in pigs. 99mTc-4ASboroxime is an excellent blood pool agent with the potential for diagnosis and prognosis of vascular diseases.
- 30 November 2017
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 28 (12) , 2998-3006
Novel Approach for 99mTc-Labeling of Red Blood Cells: Evaluation of 99mTc-4SAboroxime as a Blood Pool Imaging Agent
Angiography with radiolabeled red blood cells (RBCs) plays an important role in diagnosis and prognosis in vascular diseases. Both in vitro and in vivo methods have been developed for 99mTc-labeling of RBCs. However, these methods are complicated and lack reproducibility. Therefore, it is highly desirable to develop an alternative method for routine 99mTc-labeling of RBCs. In this report, we present a novel approach for 99mTc-labeling of RBCs. We prepared a new 99mTc(III) radiotracer [99mTcCl(CDO)(CDOH)2B-4AS] (99mTc-4ASboroxime: 4AS-B(OH)2 = 4-aminosulfonylphenyl)boronic acid, and CDOH2 = cyclohexanedione dioxime) in >95% radiochemical purity. Imaging and biodistribution studies were performed in Sprague–Dawley (SD) rats. It was found that the blood radioactivity was ∼6.0%ID/g (∼90% injected dose for 200–225 g SD rats) for 99mTc-4ASboroxime with low uptake in the myocardium, kidneys, liver, lungs, and muscle, most likely due to lack of leakage of 99mTc-labeled RBCs from the intravascular space. The blood radioactivity was almost unchanged over the 2 h period, suggesting that the binding of 99mTc-4ASboroxime to blood components (cells, proteins, and plasma) is stable. The results from γ-counting of the isolated blood components showed that 99mTc-4ASboroxime had >95% of blood radioactivity binding to RBCs, ∼1% to albumin, and ∼3% remaining free in blood plasma, demonstrating its RBC-specificity. The results from imaging studies in SD rats indicated that 99mTc-4ASboroxime is predominantly distributed in the blood pool. Main blood vessels were well delineated in the head/neck and abdominal regions. This statement was further substantiated by the results from imaging studies in pigs. 99mTc-4ASboroxime is an excellent blood pool agent with the potential for diagnosis and prognosis of vascular diseases.
- 31 May 2017
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 46 (42) , 14509-14518
99m Tc-3Cboroxime: a novel 99m Tc( iii ) complex [ 99m TcCl(CDO)(CDOH) 2 B-3C] (CDOH 2 = cyclohexanedione dioxime; 3C-B(OH) 2 = 3-(carbamoylphenyl)boronic acid) with high heart uptake and long myocardial retention
In this study, we found that 99m Tc-3Cboroxime has the myocardial retention longer than that of 99m Tc-Teboroxime, and its heart washout kinetics follows a regressive linear relationship over the 60 min period.
- 31 May 2017
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 46 (42) , 14509-14518
99m Tc-3Cboroxime: a novel 99m Tc( iii ) complex [ 99m TcCl(CDO)(CDOH) 2 B-3C] (CDOH 2 = cyclohexanedione dioxime; 3C-B(OH) 2 = 3-(carbamoylphenyl)boronic acid) with high heart uptake and long myocardial retention
In this study, we found that 99m Tc-3Cboroxime has the myocardial retention longer than that of 99m Tc-Teboroxime, and its heart washout kinetics follows a regressive linear relationship over the 60 min period.
- 1 May 2017
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 48, 1-8
Iminodiacetic acid as bifunctional linker for dimerization of cyclic RGD peptides
- 1 May 2017
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 48, 1-8
Iminodiacetic acid as bifunctional linker for dimerization of cyclic RGD peptides
- 1 November 2016
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (11) , 732-741
Novel 99m Tc(III)-azide complexes [ 99m Tc(N 3 )(CDO)(CDOH) 2 B-R] (CDOH 2 = cyclohexanedione dioxime) as potential radiotracers for heart imaging
- 1 November 2016
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (11) , 732-741
Novel 99m Tc(III)-azide complexes [ 99m Tc(N 3 )(CDO)(CDOH) 2 B-R] (CDOH 2 = cyclohexanedione dioxime) as potential radiotracers for heart imaging
- 24 October 2016
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 27 (11) , 2770-2779
Novel 99mTc(III) Complexes [99mTcCl(CDO)(CDOH)2B–R] (CDOH2 = Cyclohexanedione Dioxime) Useful as Radiotracers for Heart Imaging
In this study, we evaluated seven new 99mTc(III) complexes [99mTcCl(CDO)(CDOH)2B–R] (99mTc–2Fboroxime: R = 2-formylfuran-3-yl (2F); 99mTc–3Fboroxime: R = furan-3-yl (3F); 99mTc–5Fboroxime: R = 5-formyfuran-2-yl (5F); 99mTc–HPboroxime: R = 6-hydroxylpyridin-2-yl (HP); 99mTc–MPYboroxime: R = 5-methoxypyridin-3-yl (MPY); 99mTc–PMboroxime: R = 1,5-pyrimidin-3-yl (PM); and 99mTc–4PYboroxime: R = pyridin-4-yl (4PY)) for their potential as heart imaging agents. All new 99mTc(III) radiotracers except 99mTc–2Fboroxime were prepared with high radiochemical purity (RCP > 95%). The low RCP (∼75%) for 99mTc–2Fboroxime is most likely caused by steric hindrance from the 3-formyl group. Biodistribution and imaging studies were performed in SD rats. Planar image quantification was performed to compare their myocardial retention times. We found that the myocardial washout curves of new 99mTc(III) radiotracers were best fitted the biexponential decay function. The AUC (area under the curve) values followed the general trend: 99mTc–5Fboroxime (129 ± 6) > 99mTc–3Fboroxime (114 ± 11) > 99mTc–Teboroxime (104 ± 16) > 99mTc–MPYboroxime (92 ± 18) > 99mTc–4PYboroxime (77 ± 10) > 99mTc–PMboroxime (68 ± 14) ≈ 99mTc–HPboroxime (62 ± 14). The 2 min heart uptake values from biodistribution studies follow the ranking order of 99mTc–5Fboroxime (3.75 ± 0.15%ID/g) ≈ 99mTc–MPYboroxime (3.73 ± 0.24%ID/g) > 99mTc–PMboroxime (3.47 ± 0.15%ID/g) ≈ 99mTc–3Fboroxime ≈ (3.25 ± 0.77%ID/g). The 5 min heart uptake of 99mTc–5Fboroxime (3.91 ± 0.09%ID/g) was almost identical to its 2 min heart uptake (3.75 ± 0.15%ID/g), and its 15 min heart uptake value (2.83 ± 0.08%ID/g) compared well to the 2 min heart uptake of 99mTc–Teboroxime (3.00 ± 0.37%ID/g). It took ∼5 min for 99mTc–5Fboroxime to approach the 1 min heart uptake value of 99mTc–Teboroxime (∼3.5% ID/g) and ∼9.5 min to reach the 2 min heart uptake value of 99mTc–Teboroxime (∼3.0% ID/g). The best image acquisition window is 0–5 min for 99mTc–5Fboroxime. High-quality single-photon emission computed tomography images of the rat hearts were acquired in any of the 5 min window over the first 20 min after its administration. 99mTc–5Fboroxime has significant advantages over 99mTc–Teboroxime as the radiotracer for myocardial perfusion imaging.
- 24 October 2016
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 27 (11) , 2770-2779
Novel 99mTc(III) Complexes [99mTcCl(CDO)(CDOH)2B–R] (CDOH2 = Cyclohexanedione Dioxime) Useful as Radiotracers for Heart Imaging
In this study, we evaluated seven new 99mTc(III) complexes [99mTcCl(CDO)(CDOH)2B–R] (99mTc–2Fboroxime: R = 2-formylfuran-3-yl (2F); 99mTc–3Fboroxime: R = furan-3-yl (3F); 99mTc–5Fboroxime: R = 5-formyfuran-2-yl (5F); 99mTc–HPboroxime: R = 6-hydroxylpyridin-2-yl (HP); 99mTc–MPYboroxime: R = 5-methoxypyridin-3-yl (MPY); 99mTc–PMboroxime: R = 1,5-pyrimidin-3-yl (PM); and 99mTc–4PYboroxime: R = pyridin-4-yl (4PY)) for their potential as heart imaging agents. All new 99mTc(III) radiotracers except 99mTc–2Fboroxime were prepared with high radiochemical purity (RCP > 95%). The low RCP (∼75%) for 99mTc–2Fboroxime is most likely caused by steric hindrance from the 3-formyl group. Biodistribution and imaging studies were performed in SD rats. Planar image quantification was performed to compare their myocardial retention times. We found that the myocardial washout curves of new 99mTc(III) radiotracers were best fitted the biexponential decay function. The AUC (area under the curve) values followed the general trend: 99mTc–5Fboroxime (129 ± 6) > 99mTc–3Fboroxime (114 ± 11) > 99mTc–Teboroxime (104 ± 16) > 99mTc–MPYboroxime (92 ± 18) > 99mTc–4PYboroxime (77 ± 10) > 99mTc–PMboroxime (68 ± 14) ≈ 99mTc–HPboroxime (62 ± 14). The 2 min heart uptake values from biodistribution studies follow the ranking order of 99mTc–5Fboroxime (3.75 ± 0.15%ID/g) ≈ 99mTc–MPYboroxime (3.73 ± 0.24%ID/g) > 99mTc–PMboroxime (3.47 ± 0.15%ID/g) ≈ 99mTc–3Fboroxime ≈ (3.25 ± 0.77%ID/g). The 5 min heart uptake of 99mTc–5Fboroxime (3.91 ± 0.09%ID/g) was almost identical to its 2 min heart uptake (3.75 ± 0.15%ID/g), and its 15 min heart uptake value (2.83 ± 0.08%ID/g) compared well to the 2 min heart uptake of 99mTc–Teboroxime (3.00 ± 0.37%ID/g). It took ∼5 min for 99mTc–5Fboroxime to approach the 1 min heart uptake value of 99mTc–Teboroxime (∼3.5% ID/g) and ∼9.5 min to reach the 2 min heart uptake value of 99mTc–Teboroxime (∼3.0% ID/g). The best image acquisition window is 0–5 min for 99mTc–5Fboroxime. High-quality single-photon emission computed tomography images of the rat hearts were acquired in any of the 5 min window over the first 20 min after its administration. 99mTc–5Fboroxime has significant advantages over 99mTc–Teboroxime as the radiotracer for myocardial perfusion imaging.
- 27 February 2016
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (11) , 661-669
Comparison of biological properties of 99m Tc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging
- 27 February 2016
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (11) , 661-669
Comparison of biological properties of 99m Tc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging
- Open Access
- 1 February 2016
- Published by Springer Nature in Biophysics Reports
- Vol. 2 (1) , 1-20
Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging
The integrin family comprises 24 transmembrane receptors, each a heterodimeric combination of one of 18α and one of 8β subunits. Their main function is to integrate the cell adhesion and interaction with the extracellular microenvironment with the intracellular signaling and cytoskeletal rearrangement through transmitting signals across the cell membrane upon ligand binding. Integrin αvβ3 is a receptor for the extracellular matrix proteins containing arginine–glycine–aspartic (RGD) tripeptide sequence. The αvβ3 is generally expressed in low levels on the epithelial cells and mature endothelial cells, but it is highly expressed in many solid tumors. The αvβ3 levels correlate well with the potential for tumor metastasis and aggressiveness, which make it an important biological target for development of antiangiogenic drugs, and molecular imaging probes for early tumor diagnosis. Over the last decade, many radiolabeled cyclic RGD peptides have been evaluated as radiotracers for imaging tumors by SPECT or PET. Even though they are called “αvβ3-targeted” radiotracers, the radiolabeled cyclic RGD peptides are also able to bind αvβ5, α5β1, α6β4, α4β1, and αvβ6 integrins, which may help enhance their tumor uptake due to the “increased receptor population.” This article will use the multimeric cyclic RGD peptides as examples to illustrate basic principles for development of integrin-targeted radiotracers and focus on different approaches to maximize their tumor uptake and T/B ratios. It will also discuss important assays for pre-clinical evaluations of the integrin-targeted radiotracers, and their potential applications as molecular imaging tools for noninvasive monitoring of tumor metastasis and early detection of the tumor response to antiangiogenic therapy.
- 1 February 2016
- Published by Springer Nature in Biophysics Reports
- Vol. 2 (1) , 1-20
Open AccessRadiolabeled cyclic RGD peptides as radiotracers for tumor imaging
The integrin family comprises 24 transmembrane receptors, each a heterodimeric combination of one of 18α and one of 8β subunits. Their main function is to integrate the cell adhesion and interaction with the extracellular microenvironment with the intracellular signaling and cytoskeletal rearrangement through transmitting signals across the cell membrane upon ligand binding. Integrin αvβ3 is a receptor for the extracellular matrix proteins containing arginine–glycine–aspartic (RGD) tripeptide sequence. The αvβ3 is generally expressed in low levels on the epithelial cells and mature endothelial cells, but it is highly expressed in many solid tumors. The αvβ3 levels correlate well with the potential for tumor metastasis and aggressiveness, which make it an important biological target for development of antiangiogenic drugs, and molecular imaging probes for early tumor diagnosis. Over the last decade, many radiolabeled cyclic RGD peptides have been evaluated as radiotracers for imaging tumors by SPECT or PET. Even though they are called “αvβ3-targeted” radiotracers, the radiolabeled cyclic RGD peptides are also able to bind αvβ5, α5β1, α6β4, α4β1, and αvβ6 integrins, which may help enhance their tumor uptake due to the “increased receptor population.” This article will use the multimeric cyclic RGD peptides as examples to illustrate basic principles for development of integrin-targeted radiotracers and focus on different approaches to maximize their tumor uptake and T/B ratios. It will also discuss important assays for pre-clinical evaluations of the integrin-targeted radiotracers, and their potential applications as molecular imaging tools for noninvasive monitoring of tumor metastasis and early detection of the tumor response to antiangiogenic therapy.